Digital medical services platform Teladoc Health (NYSE: TDOC) will be reporting results this Wednesday after the bell. Here’s what to expect.
Teladoc met analysts’ revenue expectations last quarter, reporting revenues of $626.4 million, down 2.2% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EBITDA estimates and full-year EBITDA guidance beating analysts’ expectations.
Is Teladoc a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Teladoc’s revenue to be flat year on year, improving from the 3% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Teladoc has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Teladoc’s peers in the online marketplace segment, some have already reported their Q4 results, giving us a hint as to what we can expect. EverQuote delivered year-on-year revenue growth of 32.5%, beating analysts’ expectations by 10.4%, and Shutterstock reported a revenue decline of 12%, falling short of estimates by 12.7%. Shutterstock traded down 12.8% following the results.
Read our full analysis of EverQuote’s results here and Shutterstock’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. Investors in online marketplace stocks have been spared in this environment as share prices are down 20.1% on average over the last month. Teladoc is down 27.3% during the same time and is heading into earnings with an average analyst price target of $8.93 (compared to the current share price of $4.56).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
